Parallax Volatility Advisers’s Clovis Oncology, Inc. CLVS Stock Holding History

Parallax Volatility Advisers’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$2K	–	3473
2022 Q1	$2K	Buy	+1,000	New	+$1.96K	﹤0.01%	2765
2020 Q1	–	Sell	-25,000	Closed	-$261K	–	2816
2019 Q4	$261K	Hold	25,000	–	–	﹤0.01%	1938
2019 Q3	$98K	Hold	25,000	–	–	﹤0.01%	1983
2019 Q2	$372K	Sell	25,000 -40,000	-62%	-$723K	﹤0.01%	1582
2019 Q1	$1.61M	Buy	+65,000	New	+$1.63M	﹤0.01%	1079
2018 Q4	–	Sell	-224,000	Closed	-$6.58M	–	4245
2018 Q3	$6.58M	Buy	+224,000	New	+$8.67M	0.01%	620
2018 Q1	–	Sell	-50,000	Closed	-$3.4M	–	4716
2017 Q4	$3.4M	Buy	50,000 +30,000	+150%	+$2.1M	﹤0.01%	734
2017 Q3	$1.65M	Buy	+20,000	New	+$1.59M	﹤0.01%	903
2017 Q1	–	Sell	-44,900	Closed	-$1.99M	–	4899
2016 Q4	$1.99M	Buy	44,900 +20,000	+80%	+$704K	﹤0.01%	973
2016 Q3	$898K	Buy	+24,900	New	+$534K	﹤0.01%	1290

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Parallax Volatility Advisers's CLVS Position: Q2 2022 in Review

Parallax Volatility Advisers sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 86,340 shares — an estimated $174K sold.

Parallax Volatility Advisers first reported a position in CLVS in Q4 2015 and held it in 10 quarters. The position peaked at $1.99M in Q3 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

Parallax Volatility Advisers reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 86,340 Clovis Oncology, Inc. shares in Q2 2022, an estimated $174K.
Parallax Volatility Advisers first reported a position in Clovis Oncology, Inc. in Q4 2015 and held it in 10 quarters.
Parallax Volatility Advisers's Clovis Oncology, Inc. position peaked at $1.99M in Q3 2017.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Parallax Volatility Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.